PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfollicle stem cells, but minoxidil and finasteride are still the main treatments.
The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hairfollicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
PP405 shows promise in activating dormant hairfollicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
To minimize hair loss while using steroids, use finasteride or dutasteride and apply topical anti-androgens like RU58841. Avoid high doses of hair-toxic steroids; prefer testosterone, nandrolone, and boldenone.